Drug Trial Radar · NCT05162222
A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Aug 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Dec 15, 2021
Primary completion
Jul 8, 2022
Study completion Jul 8, 2022
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Dec 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effects of co-administration of itraconazole or diltiazem on the single-dose pharmacokinetics of danicamtiv in healthy participants.
Conditions
- Healthy Participants
Interventions
DanicamtivDrug
Specified dose on specified days
ItraconazoleDrug
Specified dose on specified days
DiltiazemDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to 17 days
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time ((AUC(INF))Time frame: Up to 17 days
- Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration ((AUC(0-T))Time frame: Up to 17 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Unit - Dallas
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.